Mr. Christopher Moreau reports

ALGERNON PHARMACEUTICALS ANNOUNCES NAME CHANGE TO ALGERNON HEALTH

Algernon Pharmaceuticals Inc. is changing its name to Algernon Health.

The planned name change reflects the company's recent announcement that it will be focusing on the Alzheimer's disease diagnostic market with plans to establish specialized neuroimaging clinics across North America as its lead program. The clinics will feature the latest technology of U.S. Food and Drug Administration-cleared, optimized brain-specific positron emission tomography scanning systems to detect amyloid plaques in patients, providing significantly lower radiation compared with standard PET/CT machines currently in operation globally. The PET scans are covered by Medicare, Medicaid and private insurance in the United States.

Amyloid plaques are aggregates of misfolded proteins that form in the spaces between nerve cells, are known to play a central role in AD and are associated with neural degeneration. The amyloid plaques typically first develop in the areas of the brain concerned with memory and other cognitive functions. A positive amyloid confirmation through a PET scan or a spinal tap must be first established before a patient can be treated with either Kisunla or Leqembi, the two U.S. Food and Drug Administration-approved, AD monoclonal antibody treatment therapies that remove amyloid plaque from the brain. These new treatments were developed by Eli Lilly, Eisai and Biogen, respectively, and are also covered by U.S. Medicare, Medicaid and private insurance providers.

After the first AD drug treatment was approved, in a postearnings call, GE HealthCare chief executive officer Peter Arduini called it a profound growth opportunity for all providers offering PET scans and molecular imaging.

The introduction of dedicated neuroimaging clinics provides the company with a clear pathway to revenue utilizing a technology already U.S. Food and Drug Administration cleared and covered by U.S. Medicare and Medicaid and private insurance. The Algernon clinics will also offer additional brain PET scans for other forms of dementia, epilepsy, neuro-oncology and movement disorders to further expand the provision of health care to patients in need and expand clinic revenues.

This strategic entry by Algernon into dedicated neuroimaging clinics is significantly based on the fact that the vast majority of PET/CT scanners in the United States are prioritized as cancer diagnostic and theranostic tools, and are also dedicated to cardiac imaging. Consequently, there is an insufficient supply of scanners to serve the rapidly expanding AD diagnostics market.

The shortage of PET scanners for brain specific scanning also has an impact beyond immediate patient care. With 162 AD drugs under development, there is also a significant opportunity to provide brain-specific PET scan imaging services to drug development companies and contract research organizations engaged in clinical trials as another source of revenue for Algernon.

Algernon will update the market shortly on its coming expansion and growth plans, including the location of it first U.S. flagship neuroimaging clinic.

Algernon continues to be the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury. The company also owns a 20-per-cent equity position in Seyltx, a private United States-based drug development company advancing a chronic cough drug called Ifenprodil.

Algernon is currently reviewing its repurposed chronic kidney disease drug program, which features the drug repirinast as its lead molecule.

About Algernon Health

Algernon Health is a Canadian health care company focused on the provision of brain-specific PET scanning services through a planned network of new clinics in North America for the detection of Alzheimer's disease, as well as other forms of dementia, epilepsy, neuro-oncology and movement disorders. Algernon is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury. The company also owns a 20-per-cent equity position in Seyltx, a private Untied States-based drug development company advancing a chronic cough drug called Ifenprodil.

We seek Safe Harbor.